Bicycle Therapeutics plc
BCYC
$4.10
$0.092.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -98.15% | 308.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.15% | 308.68% | |||
| Cost of Revenue | 2.27% | -18.89% | |||
| Gross Profit | -2,359.39% | 104.54% | |||
| SG&A Expenses | -13.90% | 9.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.06% | -11.41% | |||
| Operating Income | -219.30% | 68.71% | |||
| Income Before Tax | -221.10% | 67.93% | |||
| Income Tax Expenses | -86.40% | 517.07% | |||
| Earnings from Continuing Operations | -201.80% | 65.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -201.80% | 65.90% | |||
| EBIT | -219.30% | 68.71% | |||
| EBITDA | -235.66% | 69.95% | |||
| EPS Basic | -200.38% | 65.92% | |||
| Normalized Basic EPS | -310.88% | 75.07% | |||
| EPS Diluted | -200.38% | 65.92% | |||
| Normalized Diluted EPS | -310.88% | 75.07% | |||
| Average Basic Shares Outstanding | 0.46% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.46% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||